Skip to main content
. 2011 Aug 31;22(10):2048–2059. doi: 10.1021/bc200288d

Figure 3.

Figure 3

PET images of 64Cu-DOTA-T/N-trastuzumab (11.1–12.9 MBq [300–345 μCi] in 200 μL 0.9% sterile saline) in mice bearing bilateral BT-474 (HER2-positive, right shoulder) and MDA-MB-468 (HER2-negative, left shoulder) tumors between 6 and 48 h postinjection. The transverse (top) and coronal (bottom) planar images intersect the center of the tumors.